glp-1 agonist alcohol IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target Frontiers | The therapeutic potential
Description
Appetite changes typically appear within two to four weeks
however, continuous use of GLP1 receptor agonists versus DPP4 inhibitors was associated with dementia risk reduction
doi: 10.1038/ncb951
Editors Note: This article was first published on Jan
Richards J, Bang N, Ratliff EL, Paszkowiak MA, Khorgami Z, Khalsa SS, et al
These results were even greater than those recorded in CVOTs
